BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pinto-Lopes P, Afonso J, Pinto-Lopes R, Rocha C, Lago P, Gonçalves R, Tavares De Sousa H, Macedo G, Camila Dias C, Magro F. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2020;26:1707-1719. [PMID: 31912883 DOI: 10.1093/ibd/izz319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zatorski H, Salaga M, Zielińska M, Mokrowiecka A, Jacenik D, Krajewska WM, Małecka-Panas E, Fichna J. Colonic inflammation induces changes in glucose levels through modulation of incretin system. Pharmacol Rep 2021;73:1670-9. [PMID: 34535873 DOI: 10.1007/s43440-021-00327-y] [Reference Citation Analysis]
2 Hyun CK. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:9139. [PMID: 34502047 DOI: 10.3390/ijms22179139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Pinto-Lopes P, Melo F, Afonso J, Pinto-Lopes R, Rocha C, Melo D, Macedo G, Dias CC, Carneiro F, Magro F; Portuguese IBD Study Group (GEDII). Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2021;12:e00320. [PMID: 33704099 DOI: 10.14309/ctg.0000000000000320] [Reference Citation Analysis]
4 Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes 2021; 12(9): 1426-1441 [PMID: 34630898 DOI: 10.4239/wjd.v12.i9.1426] [Reference Citation Analysis]
5 Huang J, Liu X, Wei Y, Li X, Gao S, Dong L, Rao X, Zhong J. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease. Front Immunol 2022;13:830863. [DOI: 10.3389/fimmu.2022.830863] [Reference Citation Analysis]